Rabbit Anti-DPYD Recombinant Antibody (10g83) (CBMAB-D1642-YC)

Hamzic, S., Schärer, D., Offer, S. M., Meulendijks, D., Nakas, C., Diasio, R. B., ... & Largiadèr, C. R. (2021). Haplotype structure defines effects of common DPYD variants c. 85T> C (rs1801265) and c. 496A> G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity. British journal of clinical pharmacology, 87(8), 3234-3243.

Wigle, T. J., Povitz, B. L., Medwid, S., Teft, W. A., Legan, R. M., Lenehan, J., ... & Kim, R. B. (2021). Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clinical and translational science, 14(4), 1338-1348.

Naushad, S. M., Hussain, T., Alrokayan, S. A., & Kutala, V. K. (2021). Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population. The Journal of Gene Medicine, 23(1), e3289.

Wörmann, B., Bokemeyer, C., Burmeister, T., Köhne, C. H., Schwab, M., Arnold, D., ... & Hofheinz, R. D. (2020). Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper. Oncology research and treatment, 43(11), 628-636.

Coenen, M. J., Paulussen, A. D., Breuer, M., Lindhout, M., Tserpelis, D. C., Steyls, A., ... & van den Bosch, B. J. (2019). Evolution of dihydropyrimidine dehydrogenase diagnostic testing in a single center during an 8-year period of time. Current Therapeutic Research, 90, 1-7.

Murphy, C., Byrne, S., Ahmed, G., Kenny, A., Gallagher, J., Harvey, H., ... & Bird, B. (2018). Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: A single-institution experience. Dose-Response, 16(4), 1559325818803042.

Shrestha, S., Zhang, C., Jerde, C. R., Nie, Q., Li, H., Offer, S. M., & Diasio, R. B. (2018). Gene‐specific variant classifier (DPYD‐varifier) to identify deleterious alleles of dihydropyrimidine dehydrogenase. Clinical Pharmacology & Therapeutics, 104(4), 709-718.

Henricks, L. M., Siemerink, E. J., Rosing, H., Meijer, J., Goorden, S. M., Polstra, A. M., ... & van Kuilenburg, A. B. (2018). Capecitabine‐based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. International Journal of Cancer, 142(2), 424-430.

Gokare, P., Finnberg, N. K., Abbosh, P. H., Dai, J., Murphy, M. E., & El-Deiry, W. S. (2017). P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Scientific reports, 7(1), 1-12.

Del Re, M., Restante, G., Di Paolo, A., Crucitta, S., Rofi, E., & Danesi, R. (2017). Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. Current Pharmaceutical Design, 23(14), 2028-2034.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols